Screener
ANI Pharmaceuticals ANIP Rare Disease and Brands — Net Interest Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| (in thousands) | Generics and Other | Rare Disease and Brands | Corporate and Unallocated | Total |
|---|---|---|---|---|
| Selling, general, and administrative expense | 1,578 | 60,719 | 29,364 | 91,661 |
| Depreciation and amortization | — | — | 19,640 | 19,640 |
| Contingent consideration fair value adjustment | — | — | (622) | (622) |
| Operating Income (Loss) | $36,494 | $52,348 | $(48,382) | $40,460 |
| Unrealized gain on investment in equity securities | — | — | $741 | $741 |
| Interest expense, net | — | — | (3,636) | (3,636) |
| Other expense, net | — | — | (468) | (468) |
| Income (Loss) Before Income Tax Expense | $36,494 | $52,348 | $(51,745) | $37,097 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's rare disease and brands — net interest expense?
- ANI Pharmaceuticals (ANIP) reported rare disease and brands — net interest expense of $0 in Q2 2026.
- What does rare disease and brands — net interest expense mean?
- Represents the net cost of financing activities allocated to the segment, calculated as interest expense minus interest income. This metric reflects the segment's reliance on debt capital and its associated servicing costs.
Ask your AI about ANI Pharmaceuticals's rare disease and brands — net interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude